Last reviewed · How we verify

NCT07111416: PRECISE DM DX

Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis

Not yet recruiting Last updated 8 August 2025
What this trial tests

trial in Type 2 Diabetes in 45 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
1 April 2026
1 May 2026

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment45
Start date1 September 2025
Primary completion1 April 2026
Estimated completion1 May 2026

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

65 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'. The main question it aims to answer is: Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population? Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07111416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing